The HS3ST1 Knockout NCI-H1299 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population generated from the NCI-H1299 human non-small cell lung cancer cell line, in which the HS3ST1 gene encoding heparan sulfate 3-O-sulfotransferase 1 has been disrupted. This loss-of-function model provides a versatile tool for studying the role of 3-O-sulfated heparan sulfate motifs in a metastatic lung carcinoma background. The polyclonal nature of the knockout pool reflects a heterogeneous population of edited cells, eliminating the need for single-cell cloning while enabling robust functional genomics studies. Researchers can employ this model to interrogate HS3ST1-dependent phenotypes in a well-characterized tumor cell context.
NCI-H1299 is an adherent epithelial cell line derived from a lymph node metastasis of a patient with non-small cell lung carcinoma, specifically large cell carcinoma. These cells harbor a homozygous TP53 null mutation, which abolishes p53-mediated tumor suppression and enhances genomic instability, making them a widely used model for studying aggressive metastatic lung cancer. The line exhibits invasive and migratory properties, and its lack of functional p53 influences DNA damage responses, apoptosis, and cell cycle control. Consequently, NCI-H1299 is frequently employed to investigate oncogenic signaling networks, drug resistance mechanisms, and the molecular underpinnings of metastasis.
HS3ST1 catalyzes the transfer of a sulfate group to the 3-O position of glucosamine residues within heparan sulfate chains, generating specific sulfation patterns that serve as high-affinity binding sites for antithrombin III. This interaction potentiates antithrombin III-mediated inhibition of coagulation factors thrombin and factor Xa, thus contributing to the anticoagulant properties of the endothelium and potentially the tumor cell surface. Beyond hemostasis, 3-O-sulfated heparan sulfate motifs also create docking sites for growth factors such as FGF2 and VEGF, facilitating their binding to cognate receptors FGFR and VEGFR, respectively. This sulfation-dependent signaling is activated by upstream regulators including the SP1 transcription factor and TGF-??, and it integrates with heparan sulfate biosynthesis pathways. HS3ST1 therefore sits at a node connecting coagulation and growth factor signaling, influencing cellular proliferation, migration, and differentiation.
In the context of NCI-H1299 cells, HS3ST1 knockout enables dissection of how 3-O-sulfated heparan sulfate contributes to the aggressive phenotype of TP53-deficient metastatic lung cancer. Loss of HS3ST1 is expected to reduce antithrombin III binding and alter FGF2/FGFR- and VEGF/VEGFR-driven signaling cascades, which commonly promote tumor growth, angiogenesis, and invasion. This model allows for the investigation of cross-talk between the coagulation system and tumor microenvironment, as well as the role of heparan sulfate modifications in viral entry mechanisms that exploit sulfated proteoglycans. The NCI-H1299 background provides a clinically relevant platform for probing these interactions in the absence of p53 tumor suppressor function.
This product supports a broad range of research applications, including functional analysis of heparan sulfate sulfation in lung cancer, modulation of growth factor signaling, anticoagulation studies, viral entry assays, and tumor microenvironment interactions. Representative experimental techniques compatible with these cells include western blotting, RT-qPCR, immunofluorescence, flow cytometry, coagulation assays measuring antithrombin-dependent factor inhibition, migration and invasion assays, proliferation assays, phospho-ERK analysis for pathway activity, and drug sensitivity screens. For further information or technical support, please contact Ascent Research.
